These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Transformation of coronary artery aneurysm to obstructive lesion and the role of collateral vessels in myocardial perfusion in patients with Kawasaki disease. Onouchi Z; Hamaoka K; Kamiya Y; Hayashi S; Ohmochi Y; Sakata K; Shiraishi I; Hayano T; Fukumochi H J Am Coll Cardiol; 1993 Jan; 21(1):158-62. PubMed ID: 8417058 [TBL] [Abstract][Full Text] [Related]
44. Ulinastatin therapy in kawasaki disease. Iwashima S; Seguchi M; Matubayashi T; Ohzeki T Clin Drug Investig; 2007; 27(10):691-6. PubMed ID: 17803344 [TBL] [Abstract][Full Text] [Related]
45. Serial analysis of regional left ventricular wall motion by two-dimensional echocardiography in patients with coronary artery enlargement after Kawasaki disease. Vogel M; Smallhorn JF; Freedom RM J Am Coll Cardiol; 1992 Oct; 20(4):915-9. PubMed ID: 1527302 [TBL] [Abstract][Full Text] [Related]
46. Aseptic meningitis as onset of Kawasaki disease. Rossi M; Siani P; Grossi A; Carannante N; Di Caprio G; Borrelli B; Sbrana F; Di Martino F; Sarno M; Tascini C Minerva Pediatr; 2020 Apr; 72(2):135-137. PubMed ID: 30654606 [No Abstract] [Full Text] [Related]
47. Neopterin, a marker of cell-mediated immune activation in human pregnancy. Fuith LC; Fuchs D; Hausen A; Hetzel H; Reibnegger G; Werner ER; Wachter H Int J Fertil; 1991; 36(6):372-5. PubMed ID: 1684963 [TBL] [Abstract][Full Text] [Related]
49. Coronary artery dilation after Kawasaki disease for children within the normal range. Crystal MA; Manlhiot C; Yeung RS; Smallhorn JF; McCrindle BW Int J Cardiol; 2009 Jul; 136(1):27-32. PubMed ID: 18619690 [TBL] [Abstract][Full Text] [Related]
50. The serum concentration of soluble interleukin-2 receptor in patients with Kawasaki disease. Teraura H; Kotani K; Minami T; Takeshima T; Shimooki O; Kajii E Ann Clin Biochem; 2017 Mar; 54(2):209-213. PubMed ID: 28081636 [TBL] [Abstract][Full Text] [Related]
51. Kawasaki disease: review of risk factors for coronary aneurysms. Koren G; Lavi S; Rose V; Rowe R J Pediatr; 1986 Mar; 108(3):388-92. PubMed ID: 3950818 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of clinical characteristics of Kawasaki syndrome and risk factors for coronary artery abnormalities among children in Denmark. Patel A; Holman RC; Callinan LS; Sreenivasan N; Schonberger LB; Fischer TK; Belay ED Acta Paediatr; 2013 Apr; 102(4):385-90. PubMed ID: 23278838 [TBL] [Abstract][Full Text] [Related]
53. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Giovannoni G; Lai M; Kidd D; Thorpe JW; Miller DH; Thompson AJ; Keir G; Feldmann M; Thompson EJ Brain; 1997 Jan; 120 ( Pt 1)():1-13. PubMed ID: 9055793 [TBL] [Abstract][Full Text] [Related]
54. Plasma MASP-1 concentration and its relationship to recovery from coronary artery lesion in children with Kawasaki disease. Song RX; Zou QM; Li XH; Xu NP; Zhang T; Fu J; Cui XD Pediatr Res; 2016 Feb; 79(2):301-7. PubMed ID: 26536449 [TBL] [Abstract][Full Text] [Related]
55. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Wang CL; Wu YT; Liu CA; Lin MW; Lee CJ; Huang LT; Yang KD Pediatrics; 2003 Feb; 111(2):E140-7. PubMed ID: 12563087 [TBL] [Abstract][Full Text] [Related]
57. Criterion for early prediction of coronary artery involvement by clinical manifestations in patients with Kawasaki disease. Ishihara H; Izumida N; Hosaki J Bull Tokyo Med Dent Univ; 1985 Jun; 32(2):77-89. PubMed ID: 3864563 [TBL] [Abstract][Full Text] [Related]
58. Possible uses of urinary neopterin and biopterin measurement. Rabinoff M Med Hypotheses; 1989 Aug; 29(4):241-3. PubMed ID: 2586350 [TBL] [Abstract][Full Text] [Related]